<DOC>
	<DOCNO>NCT02792504</DOCNO>
	<brief_summary>To evaluate safety efficacy CE/BZA real practice Korea</brief_summary>
	<brief_title>Post Marketing Surveillance To Observe Safety And Efficacy Of Duavive</brief_title>
	<detailed_description />
	<criteria>1 . Severe post menopausal vasomotor symptom uterus 2. postmenopausal osteopenia Women undiagnosed abnormal uterine bleed Women know , suspect , past history breast cancer Women know suspected estrogendependent neoplasia Women active deep venous thrombosis , pulmonary embolism , history condition Women active arterial thromboembolic disease ( example , stroke , myocardial infarction ) history condition Women receive progestin , estrogen , estrogenagonists/antagonists Women hypersensitivity ( example , anaphylaxis , angioedema ) estrogens , bazedoxifene , ingredient Women know hepatic impairment disease Women know protein C , protein S , antithrombin deficiency know thrombophilic disorder Pregnant woman , woman may become pregnant , nurse mother Women hereditary problem galactose intolerance , Lapp lactase deficiency glucose galactose malabsorption .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>